The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Open accessAbstract
The development of targeted medicine has greatly expanded treatment options and spurred new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging as a prevalent treatment in recent years. With mixed clinical success, mAbs still hold significant shortcomings, as they possess limited tumor penetration, high manufacturing costs, and the potential to develop therapeutic resistance. However, the recent discovery of "nanobodies," the smallest-known functional antibody fragment, has demonstrated significant translational potential in preclinical and clinical studies. This review highlights their various applications in cancer and analyzes their trajectory toward their translation into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O’Rourke, T., Narayanan, S., Papadopoulos, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02018 · Cited by 599
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Liu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
Ren, J., Manzardo, A., Mazzi, A., Fedele, A., & Scipioni, A. (2013) · The Scientific World Journal · doi:10.1155/2013/918514 · Cited by 490
Tumor penetrating peptides for improved drug delivery
Ruoslahti, E. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.008 · Cited by 459
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Kooijmans, S. A. A., Aleza, C. G., Roffler, S. R., van Solinge, W. W., Vader, P., & Schiffelers, R. M. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31053 · Cited by 426
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Van de Broek, B., Devoogdt, N., D’Hollander, A., Gijs, H.-L., Jans, K., Lagae, L., Muyldermans, S., Maes, G., & Borghs, G. (2011) · ACS Nano · doi:10.1021/nn1023363 · Cited by 374
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Biophysical Properties of Human Antibody Variable Domains
Ewert, S., Huber, T., Honegger, A., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01237-8 · Cited by 330
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., Bouwens, L., Lahoutte, T., De Baetselier, P., Raes, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2994 · Cited by 291
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Muruganandam, A., Tanha, J., Narang, S., & Stanimirovic, D. (2002) · The FASEB Journal · doi:10.1096/fj.01-0343fje · Cited by 260
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., von Bonin, M., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 247
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M., Dongre, A., Whang, K. A., LeGall, C., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 246
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 226
Therapeutic Anti-Cd3 Monoclonal Antibodies: From Bench to Bedside
Kuhn, C., & Weiner, H. L. (2016) · Immunotherapy · doi:10.2217/imt-2016-0049 · Cited by 195
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
Prokaryotic expression of antibodies
Arbabi-Ghahroudi, M., Tanha, J., & MacKenzie, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-6193-1 · Cited by 191
A Nanobody‐Conjugated DNA Nanoplatform for Targeted Platinum‐Drug Delivery
Wu, T., Liu, J., Liu, M., Liu, S., Zhao, S., Tian, R., Wei, D., Liu, Y., Zhao, Y., Xiao, H., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909345 · Cited by 185
The structural basis of nanobody unfolding reversibility and thermoresistance
Kunz, P., Zinner, K., Mücke, N., Bartoschik, T., Muyldermans, S., & Hoheisel, J. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26338-z · Cited by 181
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
D'Huyvetter, M., De Vos, J., Xavier, C., Pruszynski, M., Sterckx, Y. G. J., Massa, S., Raes, G., Caveliers, V., Zalutsky, M. R., Lahoutte, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0310 · Cited by 173
Desmyter, A., Decanniere, K., Muyldermans, S., & Wyns, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102107200 · Cited by 168
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Lv, G., Sun, X., Qiu, L., Sun, Y., Li, K., Liu, Q., Zhao, Q., Qin, S., & Lin, J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226712 · Cited by 168
van Driel, P. B. A. A., Boonstra, M. C., Slooter, M. D., Heukers, R., Stammes, M. A., Snoeks, T. J. A., de Bruijn, H. S., van Diest, P. J., Vahrmeijer, A. L., van Bergen en Henegouwen, P. M. P., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.014 · Cited by 166
Papadopoulos, K. P., Isaacs, R., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L. R., Garforth, S., Fedorov, E. V., Fedorov, A. A., Bonanno, J. B., Gall, C. M. L., Crowley, S. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 162
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., Henegouwen, P. M. P. V. B. E., Storm, G., & Roovers, R. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.020 · Cited by 161
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160
Xing, Y., Chand, G., Liu, C., Cook, G. J. R., O’Doherty, J., Zhao, L., Wong, N. C. L., Meszaros, L. K., Ting, H. H., & Zhao, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224170 · Cited by 160
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 158
Jailkhani, N., Ingram, J. R., Rashidian, M., Rickelt, S., Tian, C., Mak, H. H., Jiang, Z.-G., Ploegh, H. L., & Hynes, R. O. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817442116 · Cited by 158
Maussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., van Walsum, M., Vischer, H. F., Roy, M. V., Vosjan, M. J. W. D., González-Pajuelo, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498436 · Cited by 148
Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148
Localized CD47 blockade enhances immunotherapy for murine melanoma
Ingram, J. R., Blomberg, O. S., Sockolosky, J. T., Ali, L. R., Schmidt, F. I., Pishesha, N., Espinosa, C. A., Dougan, S. K., García, K. C., Ploegh, H. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710776114 · Cited by 139
Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Pérez-Chacón, G., Erce-Llamazares, A., Merino, N., Tapia‐Galisteo, A., Cuesta, Á. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07195-w · Cited by 139
Analysis of nanobody paratopes reveals greater diversity than classical antibodies
Mitchell, L. S., & Colwell, L. J. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy017 · Cited by 138
Vos, J. D., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.800478 · Cited by 138
Li, N., Fu, H., Hewitt, S. M., Dimitrov, D. S., & Ho, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706055114 · Cited by 137
Wang, Y., Wang, Y., Chen, G., Li, Y., Xu, W., & Gong, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05654 · Cited by 133
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Rashidian, M., LaFleur, M. W., Verschoor, V. L., Dongre, A., Zhang, Y., Nguyen, T. H., Kolifrath, S. C., Aref, A. R., Lau, C. J., Paweletz, C. P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905005116 · Cited by 132
Nanobody Based Dual Specific CARs
Munter, S. D., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Weening, K., Kerre, T. C. C., Abken, H., & Vandekerckhove, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020403 · Cited by 128
You, F., Wang, Y., Jiang, L., Zhu, X., Chen, D., Yuan, L., An, G., Meng, H., & Yang, L. (2019) · Europe PMC (PubMed Central) · Cited by 127
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Altıntaş, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., Henegouwen, P. M. P. V. B. E., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.007 · Cited by 121
Conrath, K., Vincke, C., Stijlemans, B., Schymkowitz, J. W. H., Decanniere, K., Wyns, L., Muyldermans, S., & Loris, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.04.050 · Cited by 120
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
Li, D., Cheng, S., Zou, S., Zhu, D., Zhu, T., Wang, P., & Zhu, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00062 · Cited by 120
Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer
Pruszyński, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00985 · Cited by 119
Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff, A. M., Börner, K., Albrecht, B., Schäfer, W., Baum, N., Haag, F., Körbelin, J., Trepel, M., Braren, I., Grimm, D., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.003 · Cited by 119
Behdani, M., Zeinali, S., Khanahmad, H., Karimipour, M., Asadzadeh, N., Azadmanesh, K., Khabiri, A., Schoonooghe, S., Habibi‐Anbouhi, M., Hassanzadeh‐Ghassabeh, G., et al. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.11.013 · Cited by 118
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
Zhang, G., Wang, L., Cui, H., Wang, X., Zhang, G., Ma, J., Han, H., He, W., Wang, W., Zhao, Y., et al. (2014) · Scientific Reports · doi:10.1038/srep03571 · Cited by 117
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M. R., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 116
Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., Gärtner, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287246 · Cited by 116
Broos, K., Keyaerts, M., Lecocq, Q., Renmans, D., Nguyen, T. T., Escors, D., Liston, A., Raes, G., Breckpot, K., & Devoogdt, N. (2017) · Oncotarget · doi:10.18632/oncotarget.16708 · Cited by 115
Megalin Contributes to Kidney Accumulation and Nephrotoxicity of Colistin
Suzuki, T., Yamaguchi, H., Ogura, J., Kobayashi, M., Yamada, T., & Iseki, K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00254-13 · Cited by 111
Ma, L., Zhu, M., Gai, J., Li, G., Chang, Q., Peng, Q., Cao, L., Chen, W., Zhang, S., & Wan, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-0571-2 · Cited by 111
Massa, P. E., Paniccia, A., Monegal, A., de Marco, A., & Rescigno, M. (2013) · Blood · doi:10.1182/blood-2012-12-474098 · Cited by 109
Driehuis, E., Spelier, S., Hernández, I. B., de Bree, R., Willems, S. M., Clevers, H. C., & Oliveira, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111880 · Cited by 109
Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types
Groeve, K. D., Deschacht, N., Koninck, C. D., Caveliers, V., Lahoutte, T., Devoogdt, N., Muyldermans, S., BAETSELIER, P. D., & Raes, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070078 · Cited by 108
Sha, H., Zou, Z., Xin, K., Bian, X., Cai, X., Lu, W., Chen, J., Chen, G., Huang, L., Blair, A. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.039 · Cited by 104
Xie, Y. J., Dougan, M. L., Ingram, J. R., Pishesha, N., Fang, T., Momin, N., & Ploegh, H. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0734 · Cited by 103
Rashidian, M., Keliher, E. J., Dougan, M. L., Juras, P. K., Cavallari, M., Wojtkiewicz, G. R., Jacobsen, J. T., Edens, J. G., Tas, J. M. J., Victora, G. D., et al. (2015) · ACS Central Science · doi:10.1021/acscentsci.5b00121 · Cited by 100
Nanobody-coupled microbubbles as novel molecular tracer
Hernot, S., Unnikrishnan, S., Du, Z., Shevchenko, T. I., Cosyns, B., Broisat, A., Toczek, J., Caveliers, V., Muyldermans, S., Lahoutte, T., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.007 · Cited by 98
Klarenbeek, A., Mazouari, K. E., Desmyter, A., Blanchetot, C., Hultberg, A., Jonge, N. D., Roovers, R. C., Cambillau, C., Spinelli, S., Del‐Favero, J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1046648 · Cited by 96
Zhang, Z., Qian, H., Huang, J., Sha, H., Zhang, H., Yu, L., Liu, B., Hua, D., & Qian, X. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s170148 · Cited by 96
Costa, S. A., Mozhdehi, D., Dzuricky, M. J., Isaacs, F. J., Brustad, E. M., & Chilkoti, A. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03837 · Cited by 96
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
van de Water, J. A. J. M., Onder, T. B., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Henegouwen, P. M. P. V. B. E., & Shah, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202832109 · Cited by 95
Self-citationFang, T., Duarte, J. N., Ling, J. J., Li, Z., Guzman, J. S., & Ploegh, H. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509432 · Cited by 95
de Bruin, R. C. G., Veluchamy, J. P., Lougheed, S. M., Schneiders, F. L., Lopez‐Lastra, S., Lameris, R., Stam, A. G. M., Sebestyén, Z., Kuball, J. H. E., Molthoff, C. F. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1375641 · Cited by 95
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages
Xavier, C., Blykers, A., Laoui, D., Bolli, E., Vaneycken, I., Bridoux, J., Baudhuin, H. V., Raes, G., Everaert, H., Movahedi, K., et al. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-018-01302-5 · Cited by 95
Harwood, S. L., Álvarez‐Cienfuegos, A., Nuñez‐Prado, N., Compte, M., Hernández‐Pérez, S., Merino, N., Bonet, J., Navarro, R., Henegouwen, P. M. P. V. B. E., Lykkemark, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1377874 · Cited by 90
Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles
Yang, Y.-S. S., Moynihan, K. D., Bekdemir, A., Dichwalkar, T., Noh, M. M., Watson, N., Melo, M. B., Ingram, J. R., Suh, H., Ploegh, H. L., et al. (2018) · Biomaterials Science · doi:10.1039/c8bm01208c · Cited by 90
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 89
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
Dougan, M. L., Ingram, J. R., Jeong, H., Mosaheb, M. M., Bruck, P. T., Ali, L. R., Pishesha, N., Blomberg, O. S., Tyler, P. M., Servos, M. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0495 · Cited by 89
Choi, J., Vaidyanathan, G., Koumarianou, E., Kang, C. M., & Zalutsky, M. R. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.003 · Cited by 85
Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells
Groof, T. W. M. D., Mashayekhi, V., Fan, T. S., Bergkamp, N. D., Toraño, J. S., van Senten, J. R., Heukers, R., Smit, M. J., & Oliveira, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00360 · Cited by 85
Heukers, R., Altıntaş, I., Raghoenath, S., Zan, E. D., Pepermans, R. A., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.001 · Cited by 83
Yin, W., Yu, X., Kang, X., Zhao, Y., Zhao, P., Jin, H., Fu, X., Wan, Y., Peng, C., & Huang, Y. (2018) · Small · doi:10.1002/smll.201802372 · Cited by 82
Rozan, C., Cornillon, A., Pétiard, C., Chartier, M., Béhar, G., Boix, C., Kerfélec, B., Robert, B., Pèlegrin, A., Chames, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1012 · Cited by 81
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
Broos, K., Lecocq, Q., Xavier, C., Bridoux, J., Nguyen, T. T., Corthals, J., Schoonooghe, S., Lion, E., Raes, G., Keyaerts, M., et al. (2019) · Cancers · doi:10.3390/cancers11060872 · Cited by 79
Immuno-targeting the multifunctional CD38 using nanobody
Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 78
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
An, N., Hou, Y. N., Zhang, Q. X., Li, T., Zhang, Q. L., Fang, C., Chen, H., Lee, H. C., Zhao, Y. J., & Du, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00584 · Cited by 78
Yuan, Y. J., Li, J., Zhu, X., Tang, X., Bao, Y., Sun, X., Huang, Y., Tian, F., Liu, X., & Yang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s127575 · Cited by 74
Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy
Fernandes, S., Fernandes, R., Sarmento, B. F. C. C., Pereira, P. M. R., & Tomé, J. P. C. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02902d · Cited by 72
Taheri, F. H., Hassani, M., Sharifzadeh, Z., Behdani, M., Arashkia, A., & Abolhassani, M. (2019) · IUBMB Life · doi:10.1002/iub.2019 · Cited by 71
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Krasniqi, A., D’Huyvetter, M., Xavier, C., der Jeught, K. V., Muyldermans, S., der Heyden, J. V., Lahoutte, T., Tavernier, J. H., & Devoogdt, N. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0554 · Cited by 70
Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells
Fenderico, N., van Scherpenzeel, R. C., Goldflam, M., Proverbio, D., Jordens, I., Kralj, T., Stryeck, S., Bass, T. Z., Hermans, G., Ullman, C. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08172-z · Cited by 69
Peyrassol, X., Laeremans, T., Gouwy, M., Lahura, V., Debulpaep, M., Damme, J. V., Steyaert, J., Parmentier, M., & Langer, I. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500888 · Cited by 67
Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer
van Brussel, A. S. A., Adams, A. L. L., Oliveira, S., Dorresteijn, B., Khattabi, M. E., Vermeulen, J. F., van der Wall, E., Mali, W. P. T. M., Derksen, P. W. B., van Diest, P. J., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0909-6 · Cited by 66
i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
Griffiths, K. R., Dolezal, O., Cao, B., Nilsson, S. K., See, H. B., Pfleger, K. D. G., Roche, M., Gorry, P. R., Pow, A., Viduka, K., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721050 · Cited by 66
Nuhn, L., Bolli, E., Massa, S., Vandenberghe, I. H. M., Movahedi, K., Devreese, B. V., Ginderachter, J. A. V., & Geest, B. G. D. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00319 · Cited by 65
Martínez-Jothar, L., Beztsinna, N., van Nostrum, C. F., Hennink, W. E., & Oliveira, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01318 · Cited by 65
Direct Injection of Functional Single-Domain Antibodies from E. coli into Human Cells
Blanco‐Toribio, A., Muyldermans, S., Frankel, G. M., & Fernández, L. Á. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015227 · Cited by 64
Fleming, B. D., Urban, D. J., Hall, M. D., Longerich, T., Greten, T. F., Pastan, I. H., & Ho, M. (2019) · Hepatology · doi:10.1002/hep.30949 · Cited by 64
Alan, R., Ezekowitz, B., & Gordon, S. (1984) · Springer eBooks · doi:10.1007/978-1-4757-1445-6_2 · Cited by 62
Generation of Immunity against Pathogens via Single-Domain Antibody–Antigen Constructs
Duarte, J. N., Cragnolini, J. J., Swee, L. K., Bilate, A. M. B., Bader, J. M., Ingram, J. R., Rashidfarrokhi, A., Fang, T., Schiepers, A., Hanke, L., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600692 · Cited by 60
van Elssen, C. H. M. J., Rashidian, M., Vrbanac, V. D., Wucherpfennig, K. W., Habre, Z. E., Sticht, J., Freund, C., Jacobsen, J. T., Cragnolini, J., Ingram, J. R., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186007 · Cited by 59
Deng, C., Xiong, J., Gu, X., Chen, X., Wu, S., Wang, Z., Wang, D., Tu, J., & Xie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16930 · Cited by 58
Kijanka, M. M., van Brussel, A. S. A., van der Wall, E., Mali, W. P. T. M., van Diest, P. J., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0166-y · Cited by 57
Lecocq, Q., Zeven, K., Vlaeminck, Y. D., Martens, S., Massa, S., Goyvaerts, C., Raes, G., Keyaerts, M., Breckpot, K., & Devoogdt, N. (2019) · Biomolecules · doi:10.3390/biom9100548 · Cited by 57
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry
Hout, A. V., Klarenbeek, A., Bobkov, V., Doijen, J., Arimont, M., Zhao, C., Heukers, R., Rimkunas, R., de Graaf, C., Verrips, T. C., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.015 · Cited by 56
Hassani, M., Taheri, F. H., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., Modarressi, M. H., & Abolhassani, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28370 · Cited by 56
Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers
Wang, D., Hu, X., Liu, C., Jia, Y., Bai, Y., Cai, C., Wang, J., Bai, L., Yang, R., Lin, C., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0225-9 · Cited by 56
Tang, J., Li, J., Zhu, X., Yuan, Y. J., Chen, D., Yuan, L., Gu, Z.-Y., Zhang, X., Qi, L., Gong, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8710 · Cited by 55
Turini, M., Chames, P., Bruhns, P., Baty, D., & Kerfélec, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2093 · Cited by 54
Smolarek, D., Hattab, C., Hassanzadeh‐Ghassabeh, G., Cochet, S., Gutiérrez, C., de Brevern, A. G., Udomsangpetch, R., Picot, J., Grodecka, M., Waśniowska, K., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0387-6 · Cited by 54
Liu, B., Wu, P., Sha, H., Qian, H., Wang, Q., Yang, Y., Yang, M., Bian, X., & Lei, C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100678 · Cited by 54
Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
Aghaee‐Bakhtiari, S. H., Rahbarizadeh, F., Hasannia, S., Ahmadvand, D., Sofla, F. J. I., & Rasaee, M. J. (2009) · Hybridoma · doi:10.1089/hyb.2008.0079 · Cited by 53
Huang, H., Wu, T., Shi, H., Wu, Y., Yang, H., Zhong, K., Wang, Y., & Liu, Y. (2019) · Chemical Communications · doi:10.1039/c9cc01391a · Cited by 53
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
Noguchi, T., Kato, T., Wang, L., Maeda, Y., Ikeda, H., Sato, E., Knuth, A. K., Gnjatic, S., Ritter, G., Sakaguchi, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3072 · Cited by 51
A bacterial type III secretion-based protein delivery tool for broad applications in cell biology
Ittig, S., Schmutz, C., Kasper, C. A., Amstutz, M., Schmidt, A., Sauteur, L., Viganò, M., Low, S. H., Affolter, M., Cornelis, G. R., et al. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201502074 · Cited by 51
Bannas, P., Well, L., Lenz, A., Rissiek, B., Haag, F., Schmid, J., Hochgräfe, K., Trepel, M., Adam, G., Ittrich, H., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1548 · Cited by 49
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Wang, C., Gao, W., Feng, M., Pastan, I. H., & Ho, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10592 · Cited by 49
A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells
Balhuizen, A., Massa, S., Mathijs, I., Turatsinze, J., Vos, J. D., Demine, S., Xavier, C., Villate, O., Millard, I., Egrise, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15417-2 · Cited by 49
Lesniak, W. G., Chu, C., Jabłońska, A., Azad, B. B., Zwaenepoel, O., Zawadzki, M., Lisok, A., Pomper, M. G., Walczak, P., Gettemans, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04347-y · Cited by 49
Tang, Z., Feng, M., Gao, W., Phung, Y., Chen, W., Chaudhary, A., Croix, B. S., Qian, M., Dimitrov, D. S., & Ho, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0731 · Cited by 48
Anti‐c‐ MET Nanobody® – a new potential drug in multiple myeloma treatment
Slørdahl, T. S., Denayer, T., Moen, S. H., Standal, T., Børset, M., Ververken, C., & Rø, T. B. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12185 · Cited by 48
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation
Chen, J., Guo, H., Jiang, H., Namusamba, M., Wang, C., Lan, T., Wang, T., & Wang, B. (2018) · International Journal of Cancer · doi:10.1002/ijc.31930 · Cited by 48
Warnders, F. J., van Scheltinga, A. G. T. T., Knuehl, C., Roy, M. V., de Vries, E. F. J., Kosterink, J. G. W., de Vries, E. G. E., & Hooge, M. N. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181586 · Cited by 47
Desmyter, A., Spinelli, S., Boutton, C., Saunders, M. J., Blanchetot, C., de Haard, H., Denecker, G., Roy, M. V., Cambillau, C., & Rommelaere, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00884 · Cited by 47
Li, Y., Zhou, C., Li, J., Liu, J., Lin, L., Li, L., Cao, D., Li, Q., & Wang, Z. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191024 · Cited by 47
Sadeghi, A., Behdani, M., Muyldermans, S., Habibi‐Anbouhi, M., & Kazemi‐Lomedasht, F. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2693 · Cited by 47
Clercq, S. D., Zwaenepoel, O., Martens, E., Vandekerckhove, J. S., Guillabert, A., & Gettemans, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1169-0 · Cited by 46
Homayouni, V., Ganjalıkhani-Hakemi, M., Rezaei, A., Khanahmad, H., Behdani, M., & Kazemi‐Lomedasht, F. (2016) · PubMed Central · doi:10.22038/ijbms.2016.7820 · Cited by 46
Zhao, C., Busch, D. J., Vershel, C. P., & Stachowiak, J. C. (2016) · Small · doi:10.1002/smll.201600493 · Cited by 44
Orienti, I., Salvati, V., Sette, G., Zucchetti, M., Bongiorno‐Borbone, L., Peschiaroli, A., Zolla, L., Francescangeli, F., Ferrari, M., Matteo, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1383-9 · Cited by 44
Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3
Bobkov, V., Arimont, M., Zarca, A. M., Groof, T. W. M. D., van der Woning, B., de Haard, H., & Smit, M. J. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.116954 · Cited by 44
Shahbazi-Gahrouei, D., & Abdolahi, M. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/609151 · Cited by 43
Ji, X., Peng, Z., Li, X., Yan, Z., Yang, Y., Zheng, Q., & Liu, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.031 · Cited by 43
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment
Farajpour, Z., Rahbarizadeh, F., Kazemi, B., & Ahmadvand, D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.069 · Cited by 42
Screening and antitumor effect of an anti‑CTLA‑4 nanobody
Wan, R., Liu, A., Hou, X., Lai, Z., Li, J., Yang, N., Tan, J., Mo, F., Hu, Z., Yang, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6131 · Cited by 42
Tintelnot, J., Baum, N., Schultheiß, C., Braig, F., Trentmann, M., Finter, J., Fumey, W., Bannas, P., Fehse, B., Riecken, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0849 · Cited by 42
Sun, X., Yan, X. H., Zhuo, W., Gu, J., Zuo, K., Liu, W., Liang, L., Gan, Y., He, G., Wan, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071984 · Cited by 41
VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells
Heukers, R., Mashayekhi, V., Ramirez-Escudero, M., de Haard, H., Verrips, T. C., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2019) · Antibodies · doi:10.3390/antib8020026 · Cited by 41
Sánchez‐Martín, D., Martinez-Torrecuadrada, J. L., Teesalu, T., Sugahara, K. N., Álvarez‐Cienfuegos, A., Ximénez‐Embún, P., Fernández-Periañez, R., Martín, M. T., Molina-Privado, I., Ruppen, I., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300013110 · Cited by 40
Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity
Fang, T., van Elssen, C. H. M. J., Duarte, J. N., Guzman, J. S., Chahal, J. S., Ling, J. J., & Ploegh, H. L. (2017) · Chemical Science · doi:10.1039/c7sc00446j · Cited by 40
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Pan, H., Liu, J., Deng, W., Xing, J., Li, Q., & Wang, Z. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s164542 · Cited by 40
Nanobody-Functionalized Polymersomes for Tumor-Vessel Targeting
Debets, M. F., Leenders, W. P. J., Verrijp, K. C. N., Zonjee, M., Meeuwissen, S. A., Otte‐Höller, I., & van Hest, J. C. M. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300039 · Cited by 39
Tian, B., Wong, W. Y., Hegmann, E., Gaspar, K. J., Kumar, P., & Chao, H. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00237 · Cited by 39
Prantner, A. M., Yin, C., Kamat, K., Sharma, K., Lowenthal, A. C., Madrid, P. B., & Scholler, N. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00789 · Cited by 39
Sadeghnezhad, G., Romão, E., Bernedo‐Navarro, R. A., Massa, S., Khajeh, K., Muyldermans, S., & Hassania, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194818 · Cited by 39
Araste, F., Ebrahimizadeh, W., Rasooli, I., Rajabibazl, M., & Gargari, S. L. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1340-1 · Cited by 38
van der Meel, R., Oliveira, S., Altıntaş, I., Heukers, R., Pieters, E. H. E., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Kok, R. J., & Schiffelers, R. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400212v · Cited by 38
Identification and characterization of Nanobodies targeting the EphA4 receptor
Schoonaert, L., Rué, L., Roucourt, B., Timmers, M., Little, S., Chávez‐Gutiérrez, L., Dewilde, M., Joyce, P. I., Curnock, A. P., Weber, P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.774141 · Cited by 38
Tabtimmai, L., Suphakun, P., Srisook, P., Kiriwan, D., Phanthong, S., Kiatwuthinon, P., Chaicumpa, W., & Choowongkomon, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29111 · Cited by 36
Baharlou, R., Tajik, N., Behdani, M., Shokrgozar, M. A., Tavana, V., Kazemi‐Lomedasht, F., Faraji, F., & Habibi‐Anbouhi, M. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1505907 · Cited by 35
Xian, Z., Ma, L., Zhu, M., Li, G., Gai, J., Chang, Q., Huang, Y., Ju, D., & Wan, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.160 · Cited by 35
Targeting of Human Antigen-Presenting Cell Subsets
Goyvaerts, C., Dingemans, J., Groeve, K. D., Heirman, C., Gulck, E. R. V., Vanham, G. L., BAETSELIER, P. D., Thielemans, K., Raes, G., & Breckpot, K. (2013) · Journal of Virology · doi:10.1128/jvi.01498-13 · Cited by 34
Nanobody–Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses
Woodham, A. W., Cheloha, R. W., Ling, J. J., Rashidian, M., Kolifrath, S. C., Mesyngier, M., Duarte, J. N., Bader, J. M., Skeate, J. G., Silva, D. M. D., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0661 · Cited by 34
Hassani, M., Taheri, F. H., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., Abdoli, S., Modarressi, M. H., & Abolhassani, M. (2019) · Iranian Biomedical Journal · doi:10.29252/ibj.24.2.81 · Cited by 34
Zhou, Z., McDougald, D. L., Devoogdt, N., Zalutsky, M. R., & Vaidyanathan, G. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00951 · Cited by 33
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity
Li, J., Zhou, C., Dong, B., Zhong, H., Chen, S., Li, Q., & Wang, Z. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235659 · Cited by 32
Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling
Rossotti, M. A., Henry, K. A., van Faassen, H., Tanha, J., Callaghan, D., Hussack, G., Arbabi‐Ghahroudi, M., & MacKenzie, C. R. (2018) · Biochemical Journal · doi:10.1042/bcj20180795 · Cited by 32
Nanobody against the E7 oncoprotein of human papillomavirus 16
Li, S., Zhang, W., Jiang, K., Shan, H., Shi, M., Chen, B., & Hua, Z. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.022 · Cited by 32
Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging
Pant, K., Neuber, C., Zarschler, K., Wodtke, J., Meister, S., Haag, R., Pietzsch, J., & Stephan, H. (2019) · Small · doi:10.1002/smll.201905013 · Cited by 32
A novel bispecific antibody, BiSS, with potent anti-cancer activities
Dong, B., Zhou, C., He, P., Li, J., Chen, S., Miao, J. H., Li, Q., & Wang, Z. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139266 · Cited by 31
Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies
Zhao, Y., Li, Y., Wu, X., Li, L., Liu, J., Wang, Y., Liu, Y., Li, Q., & Wang, Z. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1665953 · Cited by 31
Khodabakhsh, F., Norouzian, D., Vaziri, B., Cohan, R. A., Sardari, S., Mahboudi, F., Behdani, M., Mansouri, K., & Mehdizadeh, A. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1369426 · Cited by 30
Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting
Šamec, N., Jovčevska, I., Stojan, J., Zottel, A., Liović, M., Myers, M. P., Muyldermans, S., Šribar, J., Križaj, I., & Komel, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24629 · Cited by 29
Mølgaard, K., Harwood, S. L., Compte, M., Merino, N., Bonet, J., Álvarez‐Cienfuegos, A., Mikkelsen, K., Nuñez‐Prado, N., Álvarez-Méndez, A. M., Sanz, L., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2181-5 · Cited by 29
Godar, M., Morello, V., Sadi, A., Hultberg, A., Jonge, N. D., Basilico, C., Hanssens, V., Saunders, M. J., Lambrecht, B. N., Khattabi, M. E., et al. (2016) · Scientific Reports · doi:10.1038/srep31621 · Cited by 28
van Lith, S. A. M., van den Brand, D., Wallbrecher, R., van Duijnhoven, S. M. J., Brock, R. E., & Leenders, W. P. J. (2017) · ChemBioChem · doi:10.1002/cbic.201700444 · Cited by 28
Blocking EGFR Activation with Anti‐EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms
Guardiola, S., Varese, M., Sánchez‐Navarro, M., Vincke, C., Teixidò, M., García, J., Muyldermans, S., & Giralt, E. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807736 · Cited by 28
Saqafi, B., & Rahbarizadeh, F. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1549063 · Cited by 28
Broos, K., Lecocq, Q., Keersmaecker, B. D., Raes, G., Corthals, J., Lion, E., Thielemans, K., Devoogdt, N., Keyaerts, M., & Breckpot, K. (2019) · Vaccines · doi:10.3390/vaccines7030085 · Cited by 28
A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing
Li, L., He, P., Zhou, C., Jing, L., Dong, B., Chen, S., Zhang, N., Liu, Y., Miao, J. H., Wang, Z., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000099 · Cited by 27
Xing, J., Lin, L., Li, J., Liu, J., Zhou, C., Pan, H., Shu, R., Dong, B., Cao, D., Li, Q., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.003 · Cited by 27
Remodeling of the Tumor Microenvironment by a Chemokine/Anti-PD-L1 Nanobody Fusion Protein
Fang, T., Li, R., Li, Z., Cho, J., Guzman, J. S., Kamm, R. D., & Ploegh, H. L. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00078 · Cited by 27
Li, A., Xing, J., Li, L., Zhou, C., Dong, B., He, P., Li, Q., & Wang, Z. (2016) · AMB Express · doi:10.1186/s13568-016-0201-4 · Cited by 26
Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
Romão, E., Krasniqi, A., Maes, L., Vandenbrande, C., Sterckx, Y. G. ‐., Stijlemans, B., Vincke, C., Devoogdt, N., & Muyldermans, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010310 · Cited by 26
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
Montemagno, C., Cassim, S., Trichanh, D., Savary, C., Pouysségur, J., Pagès, G., Fagret, D., Broisat, A., & Ghezzi, C. (2019) · Cancers · doi:10.3390/cancers11101531 · Cited by 25
Cao, L., Li, Q., Tong, Z., Xing, Y., Xu, K., Wang, J. Y., Li, W., Zhao, J., Zhao, L., & Hong, Z. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118939 · Cited by 25
Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function
Moradi‐Kalbolandi, S., Sharifi-K, A., Darvishi, B., Majidzadeh‐A, K., Jalili, N., Sadeghi, S., Mosayebzadeh, M., Sanati, H., Salehi, M., & Farahmand, L. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.12.017 · Cited by 25
Henry, K. A., Hussack, G., Collins, C., Zwaagstra, J. C., Tanha, J., & MacKenzie, C. R. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw043 · Cited by 24
Vlaeminck, Y. D., Lecocq, Q., Giron, P., Heirman, C., Geeraerts, X., Bolli, E., Movahedi, K., Massa, S., Schoonooghe, S., Thielemans, K., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.023 · Cited by 24
Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Ahn, S., Li, J., Sun, C., Gao, K., Hirabayashi, K., Li, H., Savoldo, B., Liu, R., & Dotti, G. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0636 · Cited by 23
Wen, B., Zhao, L., Wang, Y., Qiu, C., Xu, Z., Huang, K.-L., Zhu, H., Li, Z., & Li, H. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1692217 · Cited by 23
Ahani, R., Roohvand, F., Cohan, R. A., Etemadzadeh, M. H., Mohajel, N., Behdani, M., Shahosseini, Z., Madani, N., & Azadmanesh, K. (2016) · Molecular Biotechnology · doi:10.1007/s12033-016-9973-7 · Cited by 22
A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities
Liu, Y., Wang, Y., Xing, J., Li, Y., Liu, J., & Wang, Z. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166373 · Cited by 22
Targeted Delivery of Cyclotides via Conjugation to a Nanobody
Kwon, S., Duarte, J. N., Li, Z., Ling, J. J., Cheneval, O., Durek, T., Schroeder, C. I., Craik, D. J., & Ploegh, H. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00653 · Cited by 22
Mikkelsen, K., Harwood, S. L., Compte, M., Merino, N., Mølgaard, K., Lykkemark, S., Álvarez-Méndez, A. M., Blanco, F. J., & Álvarez‐Vallina, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01791 · Cited by 22
Li, S., Jiang, K., Wang, T., Zhang, W., Shi, M., Chen, B., & Hua, Z. (2020) · Biotechnology Letters · doi:10.1007/s10529-020-02823-2 · Cited by 21
Reshadmanesh, A., Rahbarizadeh, F., Ahmadvand, D., & Sofla, F. J. I. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1489269 · Cited by 20
Togtema, M., Hussack, G., Dayer, G., Teghtmeyer, M. R., Raphael, S., Tanha, J., & Zehbe, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092088 · Cited by 20
Tian, B., Wong, W. Y., Uger, M. D., Wiśniewski, P., & Chao, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00956 · Cited by 19
Wang, W., Hou, X., Yang, X., Liu, A., Tang, Z., Mo, F., Yin, S., & Lü, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10320 · Cited by 19
Wang, H., Wang, Y., Xiao, Z., Li, W., Dimitrov, D. S., & Chen, W. (2019) · Antibodies · doi:10.3390/antib8010025 · Cited by 18
Khatibi, A. S., Roodbari, N. H., Majidzade-A, K., Yaghmaei, P., & Farahmand, L. (2019) · Immunotherapy · doi:10.2217/imt-2019-0068 · Cited by 18
Tang, Z., Mo, F., Liu, A., Duan, S., Yang, X., Liu, L., Hou, X., Yin, S., Jiang, X., Vasylieva, N., et al. (2019) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2019.2859 · Cited by 18
Cited by
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
Zhang, H., Han, Y., Yang, Y., Lin, F., Li, K., Kong, L., Liu, H., Dang, Y., Lin, J., & Chen, P. R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08521 · Cited by 292
Structural Modeling of Nanobodies: A Benchmark of State-of-the-Art Artificial Intelligence Programs
(2023) · doi:10.3390/molecules28103991 · Cited by 39
Metadata
- Authors
- Yang, E. Y., & Shah, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-23
- Volume
- 10
- Pages
- 1182-1182
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3044721763
- Cited by
- 291
- References
- 212
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.